



<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  (PTO-1449)	ATTY. DOCKET NO. <b>066783-0145</b>	SERIAL NO. <b>10/782,375</b>
	APPLICANT <b>Pulst et al.</b>	
	FILING DATE <b>February 18, 2004</b>	GROUP <b>1645</b>

**U.S. PATENT DOCUMENTS**

EXAMINER'S INITIALS	CITE NO.	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	US 2002/0155577	10-24-2002		

**FOREIGN PATENT DOCUMENTS**

EXAMINER'S INITIALS	CITE NO.	Foreign Patent Document Country Codes-Number & Kind Codes (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Figures Appear	Translation Yes No
	2.	WO 02/24721	03-28-2002			

**OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)**

EXAMINER'S INITIALS	CITE NO.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	3.	ABBAS et al., "A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease," <u>Hum. Mol. Genet.</u> 8:567-574 (1999).	
	4.	BEITES et al., "The septin CDCrel-1 binds syntaxin and inhibits exocytosis," <u>Nat. Neurosci.</u> 2(5):434-439 (1999).	
	5.	BERTON et al., "Synaptotagmin I and IV define distinct populations of neuronal transport vesicles," <u>Eur. J. Neurosci.</u> 12:1294-1302 (2000).	
	6.	BOMMERT et al., "Inhibition of neurotransmitter release by C2-domain peptides implicates synaptotagmin in exocytosis," <u>Nature</u> 363:163-165 (1993).	
	7.	BONIFATI et al., "Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism," <u>Science</u> 299:256-259 (2003).	
	8.	CHUNG et al., "Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease," <u>Nat. Med.</u> 7:1144-1150 (2001).	
	9.	CORTI et al., "The p38 subunit of the aminoacyl-tRNA synthetase complex is a Parkin substrate: linking protein biosynthesis and neurodegeneration," <u>Hum Mol. Genet.</u> 12:1427-1437 (2003).	
	10.	DAMIER et al., "The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease," <u>Brain</u> 122:1437-1448 (1999).	
	11.	DAVIS et al., "Kinetics of synaptotagmin responses to Ca <sup>2+</sup> and assembly with the core SNARE complex onto membranes," <u>Neuron</u> . 24:363-376 (1999).	

EXAMINER	DATE CONSIDERED
----------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

\*\* This reference not attached. Will be provided under separate cover.

<b>INFORMATION DISCLOSURE</b> <b>CITATION IN AN</b> <b>APPLICATION</b>  <b>(PTO-1449)</b>		ATTY. DOCKET NO. <b>066783-0145</b>	SERIAL NO. <b>10/782,375</b>
		APPLICANT <b>Pulst et al.</b>	
		FILING DATE <b>February 18, 2004</b>	GROUP <b>1645</b>
	12.	DIANTONIO et al., "The effect on synaptic physiology of synaptotagmin mutations in <i>Drosophila</i> ," <u>Neuron</u> 12:909-920 (1993).	
	13.	DIANTONIO et al., "Synaptic transmission persists in synaptotagmin mutants of <i>Drosophila</i> ," <u>Cell</u> 73:1281-1290 (1993).	
	14.	ELFERINK et al., "A role for synaptotagmin (p65) in regulated exocytosis," <u>Cell</u> 72:153-159 (1993).	
	15.	ENGELENDER et al., "Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions," <u>Nat. Genet.</u> 22:110-114 (1999).	
	16.	FERNANDEZ-CHACON et al., "Synaptotagmin I functions as a calcium regulator of release probability," <u>Nature</u> 410:41-49 (2001).	
	17.	FINNEY et al., "The cellular protein level of parkin is regulated by its ubiquitin-like domain," <u>J. Biol. Chem.</u> 278:16054-16058 (2003).	
	18.	FUKUDA and MIKOSHIBA, "Characterization of KIAA1427 protein as an atypical synaptotagmin (Syt XIII)," <u>Biochem. J.</u> 354:249-257 (2001).	
	15.	FUKUDA et al., "A unique spacer domain of synaptotagmin IV is essential for Golgi localization," <u>J. Neurochem.</u> 77:730-740 (2001).	
	20.	FUKUDA et al., "Nerve growth factor-dependent sorting of synaptotagmin IV protein to mature dense-core vesicles that undergo calcium-dependent exocytosis in PC12 cells," <u>J. Biol. Chem.</u> 278:3220-3226 (2003).	
	21.	GEPPERT et al., "Synaptotagmin I: a major Ca <sup>2+</sup> sensor for transmitter release at a central synapse," <u>Cell</u> 79(4):717-727 (1994).	
	22.	GERONA et al., "The C terminus of SNAP25 is essential for Ca <sup>2+</sup> -dependent binding of synaptotagmin to SNARE complexes," <u>J. Biol. Chem.</u> 275:6328-6336 (2000).	
	23.	HAYASHI et al., "An autopsy case of autosomal-recessive juvenile parkinsonism with a homozygous exon 4 deletion in the parkin gene," <u>Mov. Disord.</u> 15:884-888 (2000).	
	24.	HUYNH et al., "Parkin is associated with actin filaments in neuronal and nonneuronal cells," <u>Ann. Neurol.</u> 48:737-744 (2000).	
	25.	HUYNH et al., "Parkin colocalizes with actin filaments and synaptic vesicles, and interacts with synaptotagmin XI," <u>Abstr. Soc. Neurosci.</u> 27:607, abstract 233.1, (2001).	
	26.	HUYNH et al., "Interaction of Parkin with vesicle-associated proteins," <u>Neurology</u> 58 (suppl. 3); A410 abstract S53.007 (2002).	
	27.	HUYNH et al., "The autosomal recessive juvenile Parkinson disease gene product, parkin, interacts with and ubiquitinates synaptotagmin XI," <u>Hum. Mol. Genet.</u> 12(20):2587-2597 (2003).	
	28.	IBATA et al., "Synaptotagmin IV is present at the golgi and distal parts of neuritis," <u>J. Neurochem.</u> 74:518-526 (2000).	
	29.	IMAI et al., "An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin," <u>Cell</u> 105:891-902 (2001).	

EXAMINER	DATE CONSIDERED
----------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

\*\* This reference not attached. Will be provided under separate cover.



<b>INFORMATION DISCLOSURE</b> <b>CITATION IN AN</b> <b>APPLICATION</b>  <b>(PTO-1449)</b>		ATTY. DOCKET NO. <b>066783-0145</b>	SERIAL NO. <b>10/782,375</b>
		APPLICANT <b>Pulst et al.</b>	
		FILING DATE <b>February 18, 2004</b>	GROUP <b>1645</b>
	30.	IMAI et al., "CHIP is associated with Parkin, a gene responsible for familial Parkinson's disease, and enhances its ubiquitin ligase activity," <u>Mol. Cell.</u> 10:55-67 (2002).	
	31.	IMAI et al., "Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity," <u>J. Biol. Chem.</u> 275:35661-35664 (2000).	
	32.	ISHIKAWA and TAKAHASHI, "Clinical and neuropathological aspects of autosomal recessive juvenile parkinsonism," <u>J. Neurol.</u> 245(Suppl 3): p.4 – p.9 (1998).	
	33.	ISHIKAWA and TSUJI, "Clinical analysis of 17 patients in 12 Japanese families with autosomal-recessive type juvenile parkinsonism," <u>Neurology</u> 47:160-166 (1996).	
	34.	JOAZEIRO and WEISSMAN, "RING finger proteins: mediators of ubiquitin ligase activity," <u>Cell</u> 102:549-552 (2000).	
	35.	JORGENSEN et al., "Defective recycling of synaptic vesicles in synaptotagmin mutants of <i>Caenorhabditis elegans</i> ," <u>Nature</u> 378:196-199 (1995).	
	36.	KITADA et al., "Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism," <u>Nature</u> 392:605-608 (1998).	
	37.	LE et al., "Mutations in NR4A2 associated with familial Parkinson disease," <u>Nat. Genet.</u> 33:85-89 (2003).	
	38.	LEVEQUE et al., "Calcium-dependent dissociation of synaptotagmin from synaptic SNARE complexes," <u>J. Neurochem.</u> 74:367-374 (2000).	
	39.	LI et al., "Ca <sup>2+</sup> -dependent and -independent activities of neural and non-neural synaptotagmins," <u>Nature</u> 375:594-599 (1995).	
	40.	MATSUMINE, "A loss-of-function mechanism of nigral neuron death without Lewy body formation: autosomal recessive juvenile parkinsonism (AR-JP)," <u>J. Neurol.</u> 245(Suppl 3):10-14 (1998).	
	41.	MORI et al., "Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q," <u>Neurology</u> 51:890-892 (1998).	
	42.	MURPHEY and GODENSCHWEGE, "New roles for ubiquitin in the assembly and function of neuronal circuits," <u>Neuron</u> 36:5-8 (2002).	
	43.	NAOI et al., "Cell death of dopamine neurons in aging and Parkinson's disease," <u>Mech. Ageing Dev.</u> 111:175-188 (1999).	
	44.	POLYMEROPOULOS et al., "Mutation in the alpha-synuclein gene identified in families with Parkinson's disease," <u>Science</u> 276:2045-2047 (1997).	
	45.	REIST et al., "Morphologically docked synaptic vesicles are reduced in synaptotagmin mutants of <i>Drosophila</i> ," <u>J. Neurosci.</u> 18:7662-7673 (1998).	
	46.	REN et al., "Parkin binds to alpha/beta tubulin and increases their ubiquitination and degradation," <u>J. Neurosci.</u> 23:3316-3324 (2003).	
	47.	RIBEIRO et al., "Synphilin-1 is developmentally localized to synaptic terminals, and its association with synaptic vesicles is modulated by alpha-synuclein," <u>J. Biol. Chem.</u> 277:23927-23933 (2002).	

EXAMINER	DATE CONSIDERED
----------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

\*\* This reference not attached. Will be provided under separate cover.

<b>INFORMATION DISCLOSURE</b> <b>CITATION IN AN</b> <b>APPLICATION</b>  <b>(PTO-1449)</b>		ATTY. DOCKET NO. <b>066783-0145</b>	SERIAL NO. <b>10/782,375</b>
		APPLICANT <b>Pulst et al.</b>	
		FILING DATE <b>February 18, 2004</b>	GROUP <b>1645</b>
	48.	SCHIAVO et al., "Binding of the synaptic vesicle v-SNARE, synaptotagmin, to the plasma membrane t-SNARE, SNAP-25, can explain docked vesicles at neurotoxin-treated synapses," <u>Proc. Natl. Acad. Sci. USA</u> 94:997-1001 (1997).	
	49.	SCHLOSSMACHER et al., "Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies," <u>Am. J. Pathol.</u> 160:1655-1667 (2002).	
	50.	SCOLES et al., "Neurofibromatosis 2 tumour suppressor schwannomin interacts with betall-spectrin," <u>Nat. Genet.</u> 18:354-359 (1998).	
	51.	SHIBATA et al., "A novel protein with RNA-binding motifs interacts with ataxin-2," <u>Hum. Mol. Genet.</u> 9:1303-1313 (2000).	
	52.	SHIMURA et al., "Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase," <u>Nat. Genet.</u> 25:302-305 (2000).	
	** 53.	SHIMURA et al., "Immunohistochemical and subcellular localization of Parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients," <u>Ann. Neurol.</u> 45:668-672 (1999).	
	54.	SHIMURA et al., "Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease," <u>Science</u> 293(5528):263-269 (2001).	
	55.	STAROPOLI et al., "Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity," <u>Neuron</u> 37:735-749 (2003).	
	56.	SUDHOF, "Synaptotagmins: why so many?," <u>J. Biol. Chem.</u> 277(10):7629-7632 (2001).	
	57.	TSAI et al., "Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function," <u>J. Biol. Chem.</u> 278:22044-22055 (2003).	
	** 58.	VAN DE WARRENBURG et al., "Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations," <u>Neurology</u> 56:555-557 (2001).	
	59.	VOETS et al., "Intracellular calcium dependence of large dense-core vesicle exocytosis in the absence of synaptotagmin I," <u>Proc. Natl. Acad. Sci. USA</u> 98:11680-11685 (2001).	
	60.	VON POSER et al., "The evolutionary pressure to inactivate. A subclass of synaptotagmins with an amino acid substitution that abolishes Ca <sup>2+</sup> binding," <u>J. Biol. Chem.</u> 272:14314-14319 (1997).	
	61.	WAKABAYASHI et al., "Immunocytochemical localization of synphilin-1, an alpha-synuclein-associated protein, in neurodegenerative disorders," <u>Acta Neuropathol</u> 103(3):209-214 (2002)	
	** 62.	WAKABAYASHI et al., "Synphilin-1 is present in Lewy bodies in Parkinson's disease," <u>Ann. Neurol.</u> 47:521-523 (2000).	
	63.	WANG et al., "Synaptotagmin modulation of fusion pore kinetics in regulated exocytosis of dense-core vesicles," <u>Science</u> 294:1111-1115 (2001).	
	64.	WINTERMEYER et al., "Mutation analysis and association studies of the UCHL1 gene in German Parkinson's disease patients," <u>Neuroreport</u> 11:2079-2082 (2000).	

EXAMINER	DATE CONSIDERED
----------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

\*\* This reference not attached. Will be provided under separate cover.



<b>INFORMATION DISCLOSURE</b> <b>CITATION IN AN</b> <b>APPLICATION</b>  <b>(PTO-1449)</b>		ATTY. DOCKET NO. <b>066783-0145</b>	SERIAL NO. <b>10/782,375</b>
		APPLICANT <b>Pulst et al.</b>	
		FILING DATE <b>February 18, 2004</b>	GROUP <b>1645</b>
	65.	YAMADA et al., "Relative sparing in Parkinson's disease of substantia nigra dopamine neurons containing calbindin-D <sub>28K</sub> ," <u>Brain Res.</u> 526:303-307 (1990).	
	66.	ZHANG et al., "Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1," <u>Proc. Natl. Acad. Sci. USA</u> 97:13354-13359 (2000).	
	67.	ZHANG et al., "Synaptotagmin I is a high affinity receptor for clathrin AP-2: implications for membrane recycling," <u>Cell</u> 78:751-760 (1994).	
	68.	Database EMBL accession no. BI041917	
	69.	Database EMBL accession no. BG704658	
	70.	GenBank accession number AI143229	
	71.	GenBank accession number AL135049	
	72.	GenBank accession number AW374529	
	73.	GenBank accession number BC039205	
	74.	GenBank accession number BC058917	
	75.	GenBank accession number BE899012	
	76.	GenBank accession number BE909317	
	77.	GenBank accession number BF666086	
	78.	GenBank accession number BF837913	
	79.	GenBank accession number BG113587	
	80.	GenBank accession number BG698661	
	81.	GenBank accession number BG745175	
	82.	GenBank accession number BG745915	
	83.	GenBank accession number BG765308	
	84.	GenBank accession number BI041917	
	85.	GenBank accession number BM910986	
	86.	GenBank accession number BM975158	
	87.	GenBank accession number BU542453	
	88.	GenBank accession number BU687172	
	89.	GenBank accession number CD614570	
	90.	GenBank accession number CD614574	
	91.	GenBank accession number CD614576	
	92.	GenBank accession number CD614588	
	93.	GenBank accession number CD614590	
	94.	GenBank accession number CD614592	

EXAMINER	DATE CONSIDERED
----------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

\*\* This reference not attached. Will be provided under separate cover.

<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  (PTO-1449)		ATTY. DOCKET NO. <b>066783-0145</b>		SERIAL NO. <b>10/782,375</b>	
		APPLICANT <b>Pulst et al.</b>			
		FILING DATE <b>February 18, 2004</b>		GROUP <b>1645</b>	
	95.	GenBank accession number CD614594			
	96.	GenBank accession number CD614596			
	97.	GenBank accession number CD614598			

EXAMINER	DATE CONSIDERED
----------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

\*\* This reference not attached. Will be provided under separate cover.